摘要

目的:探讨125I标记的超小超顺磁性氧化铁颗粒(ultrasmall superparamagnetic iron oxide,USPIO)偶联的贝伐珠单抗(bevacizumab)用于HepG2肝细胞肝癌模型鼠多模态显像的可行性。方法:用125I标记bevacizumab,将其经尾静脉注射入HepG2肝细胞癌肝模型鼠,注射后2 h和24 h分别进行小动物活体SPECT/CT显像。然后,用直径小于20 nm的USPIO偶联bevacizumab,合成USPIO-bevacizumab;用125I标记USPIO-bevacizumab形成125I-USPIO-bevacizumab,将其经尾静脉...